뒤로
Adaptimmune Therapeutics PLC (ADAP) 수입
ADAP 주가 차트
ADAP 수입
Adaptimmune Therapeutics PLC
$0.04
-3%
$0
종가: Mar 30, 16:00:00 GMT-4
$0.04
0%
$0
애프터마켓: Mar 30, 20:00:00 GMT-4
최신 수익 결과: Q2 '25
보고됨: 2025-08-13
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
ADAP의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Adaptimmune Therapeutics PLC ADAP의 지난 분기 매출 실적은 어땠나요?
Adaptimmune Therapeutics PLC의 매출 추정치는 얼마인가요?
Adaptimmune Therapeutics PLC의 수익 품질 점수는 얼마인가요?
Adaptimmune Therapeutics PLC는 언제 수익을 보고하나요?
Adaptimmune Therapeutics PLC의 예상 수익은 얼마인가요?
Adaptimmune Therapeutics PLC은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.05
시가
$0.0425
일일 범위
$0.0425 - $0.0599
52주 범위
$0.0001 - $0.489
거래량
1.6M
평균 거래량
3.8M
배당수익률
--
EPS(TTM)
-0.11
시가총액
$12.8M
ADAP란 무엇인가요?
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. The company is headquartered in Abingdon, Oxfordshire and currently employs 506 full-time employees. The company went IPO on 2015-05-06. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). The company is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.